TherapeuticsMD (NASDAQ:TXMD) Posts Earnings Results, Beats Estimates By $0.06 EPS

TherapeuticsMD (NASDAQ:TXMD) announced its quarterly earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.06, reports. The business had revenue of $8.21 million during the quarter, compared to the consensus estimate of $8.05 million. TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The business’s revenue was up 136.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.16) EPS.

NASDAQ TXMD traded up $0.03 during trading hours on Friday, reaching $2.85. The company’s stock had a trading volume of 3,618,659 shares, compared to its average volume of 3,304,973. The stock has a market cap of $734.74 million, a PE ratio of -4.83 and a beta of 1.65. TherapeuticsMD has a fifty-two week low of $1.82 and a fifty-two week high of $6.09. The company’s 50-day moving average is $3.46 and its two-hundred day moving average is $3.09. The company has a debt-to-equity ratio of 24.29, a quick ratio of 4.99 and a current ratio of 5.17.

A number of equities analysts have recently issued reports on TXMD shares. Noble Financial reiterated a “buy” rating and issued a $13.00 price target on shares of TherapeuticsMD in a report on Friday, September 27th. Stifel Nicolaus lowered their price objective on shares of TherapeuticsMD from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Oppenheimer set a $9.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Thursday, August 22nd. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Jefferies Financial Group lowered their price objective on shares of TherapeuticsMD from $4.00 to $3.00 and set a “hold” rating on the stock in a research note on Monday, July 15th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $10.11.

In other news, insider John C.K. Iv Milligan purchased 10,000 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $2.93 per share, with a total value of $29,300.00. Following the purchase, the insider now directly owns 1,472,419 shares of the company’s stock, valued at $4,314,187.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Angus C. Russell purchased 35,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were purchased at an average cost of $2.83 per share, for a total transaction of $99,050.00. Following the completion of the purchase, the director now directly owns 73,500 shares in the company, valued at $208,005. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 216,144 shares of company stock worth $606,348. 18.91% of the stock is owned by corporate insiders.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Further Reading: Why do earnings reports matter?

Earnings History for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.